Bullish BLSH 深 沪
交易中 06-25 10:49:12 美东时间
23.27
-0.180
-0.77%
华盛通- 最 高26.00
- 今 开23.65
- 成交量 41.06万股
- 最 低 22.70
- 昨 收 23.45
- 总市值 0
- 52周最高 118.00
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 22.70
- 委 比 -23.53%
- 总股本 --
- 历史最高 118.00
- 量 比 0
- 振 幅 14.07%
- 历史最低 22.70
- 每 手 1
- 风险率 12.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多WidePoint Stock Jumps As Huge DHS Contract Sparks Investor Excitement
WidePoint stock surged after DHS named it sole awardee for a $3.1B wireless services contract, boosting investor interest.
今天 21:41
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.
今天 01:41
Toast Shares Heat Up: TOST Joining S&P MidCap 400
Toast Inc (NYSE: TOST) shares are trading higher Wednesday morning following news that the company is moving up in the index world.
06-24 22:05
Micron's Run Isn't Over: Bank Of America Sees 40% More Upside
Bank of America raised Micron's price target to $1,500, implying 40% upside, as analysts see AI-driven memory shortages, pricing power and long-term supply agreements fueling a multi-year semiconductor boom.
06-24 04:45
Micron Technology Stock Hits 52-Week High - Here's Why
Micron (MU) stock jumps 6% to new highs ahead of June 24 earnings as Needham raises its price forecast to a bullish $1,550.
06-22 22:01
Bloom Energy Stock Hits Key Resistance: What Investors Need To Know
Bloom Energy shares are moving higher Monday as traders keep leaning into the company’s tariff-and-sourcing narrative.
06-22 21:35
Meta Stock Hasn’t Been This Cheap in Years. Is It a Buy?
Meta stock is underperforming the market this year. It ended the week at $577, down by 27% from its highest point last year.
06-21 03:21
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
06-19 03:29
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
06-19 01:38
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
06-19 01:38
